- Pluristem Therapeutics (PSTI +3.2%) FY15 results: Revenues: $0.4M (unch); COGS: $13K (+18.2%); R&D Expense: $23.4M (-6.0%); SG&A: $6.5M (-25.3%); Operating Loss: ($25.3M) (+9.3%); Net Loss: ($24.7M) (+8.2%); Loss Per Share: ($0.35) (+16.7%); Quick Assets: $53.1M (-9.7%).
- No guidance given.